Nathanael S. Gray conducts interdisciplinary study in the fields of Pharmacology and Neuroscience through his research. He performs multidisciplinary studies into Neuroscience and Pharmacology in his work. As part of his studies on Internal medicine, he often connects relevant subjects like G protein-coupled inwardly-rectifying potassium channel. Nathanael S. Gray merges G protein-coupled inwardly-rectifying potassium channel with G protein in his research. Nathanael S. Gray merges G protein with Receptor in his research. His research on Receptor often connects related areas such as Sphingosine-1-phosphate. In his works, Nathanael S. Gray performs multidisciplinary study on Sphingosine-1-phosphate and Sphingosine. The study of Sphingosine is intertwined with the study of Sphingosine-1-phosphate receptor in a number of ways. The study of Sphingosine-1-phosphate receptor is intertwined with the study of Internal medicine in a number of ways.
Many of his research projects under Leukemia are closely connected to Cancer research with Cancer research, tying the diverse disciplines of science together. The study of Immunology is intertwined with the study of Leukemia in a number of ways. Nathanael S. Gray connects Cancer research with Genetics in his study. His Genetics study frequently draws connections between related disciplines such as Cell culture. Nathanael S. Gray integrates several fields in his works, including Cell culture and Gene. Nathanael S. Gray integrates many fields in his works, including Gene and Downregulation and upregulation. Pharmacology and Developmental psychology are fields of study that intersect with his Neuroscience study. Nathanael S. Gray integrates Pharmacology and Psychiatry in his studies. His research on Psychiatry frequently connects to adjacent areas such as Schizophrenia (object-oriented programming).
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang;Priscilla L. Yang;Nathanael S. Gray.
Nature Reviews Cancer (2009)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett;Elena J. Edelman;Sonja J. Heidorn;Christopher Greenman;Christopher Greenman.
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.
Carson C. Thoreen;Seong A. Kang;Jae Won Chang;Qingsong Liu.
Journal of Biological Chemistry (2009)
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.
Aravind Subramanian;Rajiv Narayan;Steven M. Corsello;Steven M. Corsello;David D. Peck.
DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
Timothy R. Peterson;Mathieu Laplante;Carson C. Thoreen;Yasemin Sancak.
A unifying model for mTORC1-mediated regulation of mRNA translation
Carson Thoreen;Lynne Chantranupong;Lynne Chantranupong;Heather R. Keys;Heather R. Keys;Tim Wang.
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio;Francesco Iorio;Theo A. Knijnenburg;Theo A. Knijnenburg;Daniel J. Vis;Graham R. Bignell.
A chemical switch for inhibitor-sensitive alleles of any protein kinase
Anthony C. Bishop;Jeffrey A. Ubersax;Dejah T. Petsch;Dina P. Matheos.
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Jussi P. Koivunen;Craig Mermel;Kreshnik Zejnullahu;Carly Murphy.
Clinical Cancer Research (2008)
Rational design of inhibitors that bind to inactive kinase conformations.
Yi Liu;Nathanael S Gray.
Nature Chemical Biology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: